TFF Pharmaceuticals appoints Malcolm Fairbairn to its Board of Directors

– USA, TX –  TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Malcolm Fairbairn to its Board of Directors of the Company.

“Malcolm is a pioneer in the life science investment community, and we are pleased to welcome him to the Board of Directors of TFF Pharmaceuticals,” said Glenn Mattes, President and CEO. “We believe his experience, especially in financial transactions and operations, will be valuable as we continue to grow our business and expand into new potential partnership opportunities.”

About Malcolm Fairbairn

Mr. Fairbairn was the Founder, President and Chief Investment Officer for Ascend Capital, a $3.5 Billion Long/Short Equity fund for almost 20 years. He was instrumental in building all aspects of the firm, which had made significant investments in the healthcare and life science market segments. Prior to founding Ascend, Mr. Fairbairn was a Managing Director of Citadel Investment Group. Mr. Fairbairn holds an MBA from Harvard Business School and an MS and BS from MIT in Chemical Engineering.

“I’m very excited to join the board of TFF to aid the development of its novel drug delivery platform,” said Malcolm Fairbairn. “Their Thin Film Freezing platform technology holds strong promise for a wide variety of compounds for lung conditions, biologics and combination drugs.”

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally.

For more information: https://tffpharma.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.